



Date: 12-02-2026

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex,
Bandra East, Mumbai-400051
Scrip Code: MUKKA

BSE Limited
Listing Department
Dalal Street,
Mumbai-400001
Scrip Code: 544135

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on 12th February 2026.

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), amendment(s) or reenactment(s) thereof for the time being in force), this is to inform you that the Board of Directors of the Company at their meeting held today i.e. 12th February 2026, have inter-alia approved following business:

1. **Financial Results:** The unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months period ended 31st December 2025. The same is enclosed. Further, the Limited Review Report received from the Statutory Auditors of the Company is also enclosed.
2. **Amendment to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders:** The Board, on the recommendation of the Audit Committee has approved the amendment to the " Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders ". The amended Code is made available on the Company's website at <https://mukkaproteins.com/policy.php>.
3. **Acquisition of additional equity shares in Ento Proteins Private Limited ("EPPL"):** The Board has approved the acquisition of additional 1,000 equity shares of face value of Rs. 100/- each in EPPL from the existing shareholder, thereby making EPPL a wholly owned subsidiary of the Company.
4. **Acquisition of additional equity shares in Haris Marine Products Private Limited ("HMPPL"):** The Board has approved the acquisition of additional 2,000 equity shares of face value of Rs. 100/- each in HMPPL from the existing shareholders, thereby making HMPPL a wholly owned subsidiary of the Company.

Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihihlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - **Website :** www.mukkaproteins.com - **CIN :** L10207KA2010PLC055771



The detailed disclosure as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023 and such other circulars as applicable, in respect of point no. 3 and 4 is enclosed as Annexure I and II respectively.

The Meeting commenced at 04:00 p.m. and concluded at 4:45 p.m.

This is for your information and records.

Thank you,
For **Mukka Proteins Limited**

Mehaboobsab Mahmadgous Chalyal
Company Secretary & Compliance Officer
Membership No.: A67502


Encl: as above.

Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Mukka Proteins Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Mukka Proteins Limited** ("the Parent"), its subsidiaries (the Parent and its subsidiaries together referred to as "**the Group**") and Group's share of the net profit/loss after tax and total comprehensive income/loss of its associates and joint ventures, for the quarter and nine months ended December 31, 2025 ('the Statement') attached herein, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.




4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Mukka Proteins Limited	Parent Company
Haris Marine Products Private Limited	Subsidiary Company (Domestic)
Atlantic Marine Products Private Limited	Subsidiary Company (Domestic)
Ocean Aquatic Proteins LLC	Subsidiary Company (Foreign)
Ento Proteins Private Limited	Subsidiary Company (Domestic)
Fabbco Bio Cycle and Bio Protein Technology Private Limited	Subsidiary Company (Domestic)
Ocean Proteins Private Limited	Subsidiary Company (Domestic)
United Gulf Fishery Products LLC	Subsidiary Company (Foreign)
Mukka Frozen Impex	Subsidiary Entity (Domestic)
Ullal Fish Meal and Oil Company	Joint Venture
GSM Marine Export	Joint Venture
Progress Frozen and Fish Sterilization	Joint Venture
Pacific Marine Products	Joint Venture
Mangalore Fishmeal and Oil Company	Joint Venture – Indirect

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information/ financial results of Eight subsidiaries included in the Statement, whose interim financial information/ financial results reflect total revenues of Rs.1643.28 million and Rs.3076.18 million, total net profit after tax of Rs. 111.98 million and Rs.136.44 million and total comprehensive income of Rs. 113.95 million and Rs.132.56 million for the quarter ended December 31,2025 and year to date for the nine months ended December 31, 2025 respectively as considered in the Statement which have been reviewed by other auditors, whose reports has been furnished to us by the Company's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.


Further, we did not review the interim financial information/ financial results of Five Joint Ventures included in the Statement, whose interim financial information/ financial results reflect share of Profit amounting to Rs 12.01 million and Rs. 7.17 million and Total Comprehensive Profit amounting to Rs. 12.01 million and Rs. 7.17 million for the quarter ended December 31,2025 and year to date for the nine months ended December 31, 2025 respectively as



considered in the statement which have been reviewed by other auditors, whose reports have been furnished to us by the Company's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

For SHAH & TAPARIA
Chartered Accountants
FRN: 109463W



Bharat Joshi

Partner

M. No.: 130863

UDIN: 26130863SQDYDZ 7187

Date: February 12, 2026

Place: Mumbai

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE
QUARTER & NINE MONTHS ENDED DECEMBER 31, 2025

(Rupees in million, except per share data and if otherwise stated)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024	March 31, 2025
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	Revenue from Operations						
	Revenue from operations	6,346.37	2,360.81	2,962.04	10,355.99	6,077.64	9,800.26
	Other operating income	188.60	85.01	69.49	332.53	170.81	263.90
	Total Revenue from operations	6,534.97	2,445.81	3,031.52	10,688.52	6,248.45	10,064.16
2	Other income	49.33	59.99	57.98	134.87	117.91	151.15
3	Total income	6,584.30	2,505.81	3,089.51	10,823.39	6,366.35	10,215.31
4	Expenses						
	Cost of Material Consumed	5,819.69	2,804.52	3,418.61	10,552.67	6,615.07	9,161.04
	Changes in inventories of finished goods, stock in trade and work in progress	-310.15	-917.75	-1,209.74	-1,863.11	-1,987.51	-1,414.35
	Employee benefits expenses	108.15	89.41	84.34	276.45	237.32	323.00
	Finance costs	145.61	128.24	109.07	384.26	277.60	372.50
	Depreciation and amortisation	40.30	41.75	37.96	114.67	107.30	135.51
	Other expenses	462.86	262.40	324.78	915.31	726.51	1,045.63
	Total expenses	6,266.46	2,408.56	2,765.03	10,380.24	5,976.28	9,623.33
5	Profit before exceptional item, Share of Net Profit / (loss) of Associates and Joint Ventures and tax (3-4)	317.85	97.24	324.48	443.15	390.07	591.98
6	Exceptional items	-	-	-	-	-	-
7	Share of Net Profit / (loss) of Associates and Joint Ventures	28.35	-4.46	5.22	19.42	11.58	10.68
8	Profit before tax (5-6+7)	346.20	92.78	329.70	462.57	401.65	602.66
9	Total tax expenses						
	Current Tax	72.87	23.22	55.95	104.13	62.13	112.20
	Deferred Tax	0.79	0.93	-1.27	1.38	6.45	0.09
	Earlier years	0.00	-0.21	7.03	-0.21	-7.90	9.40
10	Profit for the period	272.53	68.84	267.99	357.27	340.97	480.97
11	Other Comprehensive Income						
	<u>Items that will not be reclassified subsequently to profit or loss</u>						
	Remeasurement of the net defined benefit plans	1.90	1.00	1.32	3.11	1.59	0.38
	<u>Items that will be reclassified subsequently to profit or loss</u>						
	Exchange differences on translation of foreign operations	8.12	-7.93	-2.67	-0.56	-4.08	-3.64
12	Total other comprehensive income	10.01	-6.93	-1.35	2.55	-2.50	-3.26
13	Total comprehensive income for the period	282.55	61.91	266.65	359.82	338.48	477.71
	Profit for the year attributable to:						
	Shareholders of the Company	237.48	58.77	262.61	315.25	328.73	464.59
	Non-controlling interests	35.06	10.07	5.38	42.02	12.24	16.38
	Other comprehensive income for the year attributable to:						
	Shareholders of the Company	7.01	-4.00	-0.36	2.92	-0.99	-1.91
	Non-controlling interests	3.00	-2.94	-0.99	-0.37	-1.51	-1.35
14	Paid-up equity share capital (Face Value of the share Re. 1/- each) *	300.00	300.00	300.00	300.00	300.00	300.00
15	Other equity	-	-	-	-	-	4,107.03
16	Earnings per share * (Face Value Rs. 1/- per share)						
	(a) Basic	0.79	0.20	0.88	1.05	1.10	1.55
	(b) Diluted	0.79	0.20	0.88	1.05	1.10	1.55

** Basic & Diluted EPS for all periods, except year ended March 31, 2025, is not annualised.
See accompanying notes to the financial results



Handwritten signature/initials in blue ink.

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
NOTES TO THE STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE
QUARTER & NINE MONTHS ENDED DECEMBER 31, 2025

- 1 The above statement of Unaudited consolidated financial results for the Quarter & Nine Months Ended December 31, 2025 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on **February 12, 2026**. The Statutory auditors have carried out a review of the consolidated financial results for the Quarter Ended December 31, 2025 and have issued an unmodified opinion on the same.
- 2 The Un-audited Consolidated Financial Results of the company are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.
- 3 The figures for the quarter ended December 31, 2025 are balancing figure between the audited figures for the Period ended December 31, 2025 and published year to date figures for Six Months ended September 30, 2025.
- 4 The Group operates in a single operating segment namely Fish & Insects Protein. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assess financials performance & allocate resources based upon discrete financial information. Since the Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below -

Revenue disaggregation by geography is as follows :-

Particulars	Quarter Ended			Nine Months ended		Year Ended
	December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024	March 31, 2025
	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
Within India	1,445.61	947.20	1,774.38	2,512.91	2,273.50	3,047.02
Outside India	4,900.76	1,413.60	1,187.66	7,843.07	3,804.13	6,753.24
Total	6,346.37	2,360.81	2,962.04	10,355.99	6,077.64	9,800.26

Acquisitions and Investments:

- 5 United Gulf Fishery Products LLC: The Company has completed the acquisition of 68% of the Share Capital of United Gulf Fishery Products LLC on 26th December 2025 for a total cash consideration of OMR 34,000 (₹7.96 Millions), pursuant to which the Company holds 68% of the paid-up capital and the entity has become its subsidiary.

Ocean Proteins Private Limited (OPPL) : The Company has completed the acquisition of 1,04,500 additional equity shares in OPPL from its existing shareholders on 30th December 2025 for a total cash consideration of ₹10.45 Millions, consequent to which the Company holds 51% equity stake in OPPL and the entity has become its subsidiary.
- Mukka Proteins Vietnam Co., Ltd.: The Company has proposed to acquire equity shares in Mukka Proteins Vietnam Co., Ltd., however, the acquisition originally expected to be completed by 31st December 2025 has been deferred due to pending regulatory approvals and, as the transaction was not completed as at the reporting date, the same has not been accounted for and has been disclosed as a significant subsequent event, with the revised expected completion date of 30th June 2026.
- 6 The Customs Department, Mangaluru has issued a Bond Enforcement Order demanding customs duty of ₹ 76.70 Millions plus applicable interest for non-submission of Export Obligation Discharge Certificates under the Advance Authorisation Scheme. The demand arises from alleged non-fulfilment of export obligations on earlier imports.

For and on behalf of Board of Directors of
Mukka Proteins Limited



Kalandan Mohammed Haris
Managing Director and CEO
DIN: 03020471



Date: February 12, 2026
Place: Mangalore

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors,
Mukka Proteins Limited

1. We have reviewed the accompanying statement of unaudited Standalone Financial Results of **Mukka Proteins Limited** ('the Company'), for the quarter and nine months ended 31st December 2025, (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") including relevant circulars issued by SEBI from time to time.
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHAH & TAPARIA

Chartered Accountants

FRN: 109463W



Bharat Joshi

Partner

M. No.: 130863

UDIN: 26130863QIGLKY6856



Date: February 12, 2026

Place: Mumbai

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE
QUARTER & NINE MONTHS ENDED DECEMBER 31, 2025

(Rupees in million, except per share data and if otherwise stated)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024	March 31, 2025
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	Revenue from operations						
	Revenue from operations	5,387.53	2,160.44	2,799.90	8,846.98	5,443.64	8,603.53
	Other operating income	195.11	62.27	69.49	316.30	170.81	263.90
	Total Revenue from operations	5,582.64	2,222.71	2,869.39	9,163.28	5,614.45	8,867.43
2	Other income	56.76	56.70	62.30	146.64	122.15	164.77
3	Total income (1+2)	5,639.40	2,279.41	2,931.69	9,309.91	5,736.60	9,032.20
4	Expenses						
	Cost of Material Consumed	5,230.77	2,545.41	3,178.33	9,491.62	5,888.82	8,197.35
	Changes in inventories of finished goods, stock in trade and work in progress	-434.32	-748.12	-1,020.78	-1,869.72	-1,627.80	-1,271.59
	Employee benefits expenses	70.99	60.77	55.27	182.72	160.68	216.40
	Finance costs	137.33	120.83	101.19	361.66	254.13	343.26
	Depreciation and amortisation expenses	15.26	14.97	13.80	43.79	45.04	58.61
	Other expenses	388.63	225.39	290.02	786.24	664.26	964.12
	Total expenses	5,408.68	2,219.25	2,617.83	8,996.31	5,385.14	8,508.14
5	Profit before exceptional item and tax (3-4)	230.72	60.15	313.86	313.60	351.46	524.06
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (5-6)	230.72	60.15	313.86	313.60	351.46	524.06
8	Share of Net Profit / (loss) of Associates and Joint Ventures	14.96	-2.08	3.06	8.12	3.78	1.74
9	Total tax expenses						
	Current Tax	56.41	19.50	55.06	83.00	55.06	98.49
	Deferred Tax	1.68	2.47	-0.73	3.68	6.37	-0.83
	Earlier years	-	-	11.57	-	7.87	11.31
10	Profit after tax (7+8-9)	187.59	36.10	251.02	235.03	285.94	416.83
11	Other Comprehensive Income/ (Expenses) (net of tax)						
	Items that will not be reclassified to profit or loss						
	-Remeasurements of the defined benefit plans	1.90	1.00	1.32	3.11	1.59	0.38
12	Other comprehensive income, net of tax	1.90	1.00	1.32	3.11	1.59	0.38
13	Total Comprehensive Income for the Period (after tax) (10+11)	189.48	37.10	252.34	238.14	287.52	417.21
13	Paid-up equity share capital (Face Value of the share Rs. 1/- each)	300.00	300.00	300.00	300.00	300.00	300.00
14	Other equity	-	-	-	-	-	3,743.66
15	Earnings per share * (Face Value Rs. 1 /- per share)						
	(a) Basic	0.63	0.12	0.84	0.79	0.96	1.39
	(b) Diluted	0.63	0.12	0.84	0.79	0.96	1.39

** Basic & Diluted EPS for all periods, except year ended March 31, 2025, is not annualised.
See accompanying notes to the financial results



MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
NOTES TO THE STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE
QUARTER & NINE MONTHS ENDED DECEMBER 31, 2025

- 1 The above statement of Un-audited standalone financial results for the Quarter & Period ended December 31, 2025 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on **February 12, 2025**. The Statutory auditors have carried out a review of the standalone financial results for the Quarter & Period ended December 31, 2025 and have issued an unmodified opinion on the same.
- 2 The Un-audited Standalone Financial Results of the company are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.
- 3 The figures for the quarter ended December 31, 2025 are balancing figure between the audited figures for the period ended December 31, 2025 and published Period to date figures for Six months ended September 30, 2025.
- 4 The Group operates in a single operating segment namely Fish & Insects Protein. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assess financials performance & allocate resources based upon discrete financial information. Since the Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below -

Revenue disaggregation by geography is as follows :-

(Rupees in Million)

Particulars	Quarter Ended			Nine Months ended		Year ended
	December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024	March 31, 2025
	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Unaudited)	(Audited)
Within India	1,210.85	913.58	1,309.17	2,239.15	1,793.42	3,034.56
Outside India	4,176.69	1,246.86	1,490.74	6,607.83	3,650.21	5,568.97
Total	5,387.53	2,160.44	2,799.90	8,846.98	5,443.64	8,603.53

- 5 The figures for comparative period have been regrouped/ reclassified, wherever necessary, to make them comparable.

6 Acquisitions and Investments:


United Gulf Fishery Products LLC: The Company has completed the acquisition of 68% of the Share Capital of United Gulf Fishery Products LLC on 26th December 2025 for a total cash consideration of OMR 34,000 (₹7.96 Millions), pursuant to which the Company holds 68% of the paid-up capital and the entity has become its subsidiary.

Ocean Proteins Private Limited (OPPL): The Company has completed the acquisition of 1,04,500 additional equity shares in OPPL from its existing shareholders on 30th December 2025 for a total cash consideration of ₹10.45 Millions, consequent to which the Company holds 51% equity stake in OPPL and the entity has become its subsidiary.

Mukka Proteins Vietnam Co., Ltd.: The Company has proposed to acquire equity shares in Mukka Proteins Vietnam Co., Ltd., however, the acquisition originally expected to be completed by 31st December 2025 has been deferred due to pending regulatory approvals and, as the transaction was not completed as at the reporting date, the same has not been accounted for and has been disclosed as a significant subsequent event, with the revised expected completion date of 30th June 2026.

- 7 The Customs Department, Mangaluru has issued a Bond Enforcement Order demanding customs duty of ₹ 76.70 Millions plus applicable interest for non-submission of Export Obligation Discharge Certificates under the Advance Authorisation Scheme. The demand arises from alleged non-fulfilment of export obligations on earlier imports.

For and on behalf of Board of Directors of
Mukka Proteins Limited


Kalandan Mohammed Haris
 Managing Director and CEO
 DIN: 03020471



Date : February 12, 2025
 Place: Mangalore



Annexure-I

S. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.;	Name of the Target entity: Ento Proteins Private Limited ("EPPL") Authorized Capital: Rs. 10,00,000/- Paid up Capital: Rs. 3,84,700/- Turnover (FY 2024-25): Rs. 7,46,27,305/- PAT (FY 2024-25): Rs. 49,47,474/-
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	EPPL is a related party of the Company as per the provisions of the Companies Act, 2013, being a Subsidiary Company. The Promoters are interested in EPPL to the extent of their directorship. The investment will be done by the Company on an arm's length basis.
3.	Industry to which the entity being acquired belongs;	Manufacturer of Insect meal and Insect oil.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The proposed investment is being made as a part of Company's strategic investment plans to expand the Alternate Proteins business of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition;	30-06-2026
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired;	Acquisition of 1,000 equity shares of face value of Rs.100/- each of EPPL for a total consideration of Rs. 32,30,000/-.
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Proposed to acquire 1,000 equity shares of face value of Rs.100/- each of EPPL for a total consideration of Rs. 32,30,000/-. Post-acquisition Shareholding will be 100%.

Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771



10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>EPPL is a Manufacturer of Insect meal and Insect oil.</p> <p>Line of Business: Manufacturer of Insect meal and Insect oil.</p> <p>Date of Incorporation: 8th March 2021</p> <p>Turnover of last 3 years:</p> <p>As on March 2023: Rs. 4,72,20,140/-</p> <p>As on March 2024: Rs. 6,44,38,907/-</p> <p>As on March 2025: Rs. 7,46,27,305/-</p> <p>Country in which the acquired entity has presence: India</p>
-----	---	--

Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (O) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771



Annexure-II

S. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.;	Name of the Target entity: Haris Marine Products Private Limited ("HMPPL") Authorized Capital: Rs. 1,00,00,000/- Paid up Capital: Rs. 1,00,00,000/- Turnover (FY 2024-25): Nil PAT (FY 2024-25): Rs. 2,24,01,700/-
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	HMPPL is a related party of the Company as per the provisions of the Companies Act, 2013, being a Subsidiary Company. The Promoters are interested in HMPPL to the extent of their shareholding and directorship. The investment will be done by the Company on an arm's length basis.
3.	Industry to which the entity being acquired belongs;	Manufacturer and Exporter of fish meal and fish oil.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The proposed investment is being made as a part of Company's strategic investment plans to expand the core business of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition;	30-06-2026
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired;	Acquisition of 2,000 equity shares of face value of Rs.100/- each of HMPPL for a total consideration of Rs. 19,64,000/-.
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Proposed to acquire 2,000 equity shares of face value of Rs.100/- each of HMPPL for a total consideration of Rs. 19,64,000/-. Post-acquisition Shareholding will be 100%.

Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771



10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>HMPPL is a Manufacturer and Exporter of fish meal and fish oil.</p> <p>Line of Business: Manufacturer and Exporter of fish meal and fish oil.</p> <p>Date of Incorporation: 30th October 2019</p> <p>Turnover of last 3 years:</p> <p>As on March 2023: Rs. 50,95,31,673/-</p> <p>As on March 2024: Nil</p> <p>As on March 2025: Nil</p> <p>Country in which the acquired entity has presence: India</p>
-----	---	---

Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (O) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771